Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: A randomized, controlled, Phase III trial
Amaia Hervás(Mútua Terrassa), Brigitte Robertson(Takeda (United States)), Vanja Sikirica(Moderna Therapeutics (United States)), A. G. Lyne(University of Manchester), Sasha Sreckovic, Michael Huß(Johannes Gutenberg University Mainz), Ralph Bloomfield(AstraZeneca (United Kingdom)), Judy van Stralen(Ontario Centre of Excellence for Child and Youth Mental Health), Mats Johnson(Sahlgrenska University Hospital), Fiona McNicholas(University College Dublin)
Cited by 79
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Computerized Training of Working Memory in Children With ADHD-A Randomized, Controlled Trial
|Journal of the American Academy of Child & Adolescent Psychiatry|2005|2k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Certolizumab Pegol for the Treatment of Crohn's Disease
|New England Journal of Medicine|2007|1.1k
Tests of General Relativity from Timing the Double Pulsar
|Science|2006|1.1k